Patents Examined by Julie Wu
  • Patent number: 10604557
    Abstract: Cysteine engineered antibodies comprising a free cysteine amino acid in the heavy chain or light chain are prepared by mutagenizing a nucleic acid sequence of a parent antibody and replacing one or more amino acid residues by cysteine to encode the cysteine engineered antibody; expressing the cysteine engineered antibody; and isolating the cysteine engineered antibody. Certain highly reactive cysteine engineered antibodies were identified by the PHESELECTOR assay. Isolated cysteine engineered antibodies may be covalently attached to a capture label, a detection label, a drug moiety, or a solid support.
    Type: Grant
    Filed: November 21, 2016
    Date of Patent: March 31, 2020
    Assignee: Genentech, Inc.
    Inventors: Sunil Bhakta, Jagath R. Junutula
  • Patent number: 10603389
    Abstract: The present disclosure provides antibody drug conjugates that bind human cMET, their methods of making, and their uses to treat patients having cancer.
    Type: Grant
    Filed: May 28, 2019
    Date of Patent: March 31, 2020
    Assignees: AbbVie Inc., AbbVie Biotherapeutics Inc.
    Inventors: Christian B. Allan, Louie Naumovski, Edward B. Reilly
  • Patent number: 10597461
    Abstract: Provided are antibodies that specifically bind to an epitope containing N-acetylglucosamine or N-acetyl-galactosamine expressed by a cancer cell or an inflammatory cell. Also provided are compositions including these antibodies, as well as polynucleotides, vectors, host cells, and methods useful for production thereof. Further provided are methods and kits for treating or preventing cancer in an individual by administering to the individual an antibody that specifically binds to an epitope containing N-acetylglucosamine or N-acetyl-galactosamine, optionally in combination with another anti-cancer agent. Still further provided are methods and kits for treating or preventing gastrointestinal disease in an individual by administering to the individual an antibody that specifically binds to an epitope containing N-acetylglucosamine or N-acetyl-galactosamine.
    Type: Grant
    Filed: August 21, 2015
    Date of Patent: March 24, 2020
    Assignee: B & H Biotechnologies, LLC
    Inventor: Huiru Wang
  • Patent number: 10597427
    Abstract: The present invention provides a diabetes-inducing bacterium and use thereof, and a reagent and a detection method for detecting the bacterium. According to the present invention, enteric colonization of the diabetes-inducing bacterium can be prevented, and diabetes can be treated and/or prevented.
    Type: Grant
    Filed: September 26, 2014
    Date of Patent: March 24, 2020
    Assignee: AJINOMOTO CO., INC.
    Inventors: Keishi Kameyama, Kikuji Itoh
  • Patent number: 10591494
    Abstract: The invention relates to an in vitro diagnosis device (10) for the detection of at least one reaction between an erythrocytic phenotype antigen and an antibody specifically directed against said antigen in a sample of blood or one of the components thereof. The device is characterized in that it comprises: a substrate (12); and a hydrophobic porous membrane (14) having a thickness of between 0.5 mm and 1.5 mm and a pore diameter of between 2 and 30 ?m, said membrane comprising at least one hydrophilic reaction zone (16) intended to receive the sample. The invention also relates to the uses of said device in immunohematology.
    Type: Grant
    Filed: June 11, 2013
    Date of Patent: March 17, 2020
    Assignee: Diagast
    Inventors: Najim Chaibi, Sylvain Malgouries, Megumi Lucas
  • Patent number: 10590188
    Abstract: The present invention provides an antibody which comprises a variable heavy (VH) chain comprising CDR1, CDR2 and CDR3, and/or a variable light (VL) chain comprising CDR1, CDR2 and CDR3, wherein the CDRs have the same amino acid sequence as those from a complete antibody isolated from a synovial tissue sample of rheumatoid arthritis patients, as listed in Tables 1 and 2 or Tables 1 A and 2 A.
    Type: Grant
    Filed: June 12, 2015
    Date of Patent: March 17, 2020
    Assignee: Queen Mary University of London
    Inventors: Michele Bombardieri, Constantino Pitzalis, Elisa Corsiero
  • Patent number: 10584178
    Abstract: The present invention relates to bispecific HER2 antibodies, novel HER2 antibody variants, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
    Type: Grant
    Filed: June 17, 2016
    Date of Patent: March 10, 2020
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Rebecca Croasdale-Wood, Lydia Jasmin Hanisch, Guy Georges, Thomas Hofer, Ralf Hosse, Christian Klein, Ekkehard Moessner, Samuel Moser, Wolfgang Schaefer, Juergen Michael Schanzer, Werner Scheuer, Claudio Sustmann, Pablo Umana
  • Patent number: 10569270
    Abstract: Methods are provided for the large-scale high-content analysis of biological samples. In some embodiments, the methods are implemented in a reversed open microwell system that includes an array of open microwells, at least one microchannel, at least one input port and at least one output port. In certain embodiments, the reversed open microwell system can be inserted in an automated management system which includes an incubator at controlled temperature, humidity and CO2 levels, a fluid dispensing system, and is capable of phase-contrast and fluorescence image acquisition. Also provided are kits for introducing fluids into a microfluidic device, and systems for discharging one or more fluids in a microfluidic device.
    Type: Grant
    Filed: June 14, 2017
    Date of Patent: February 25, 2020
    Assignee: CELLPLY S.R.L.
    Inventors: Massimo Bocchi, Andrea Faenza, Laura Rocchi, Dario Biscarini, Nicola Pecorari
  • Patent number: 10551376
    Abstract: Systems, methods, and devices for selective capture and release of target particles, e.g., living cells, from liquid samples, e.g., blood, are provided. The particle capture systems include a substrate; a first layer of gelatin bound to the substrate by physical adsorption, wherein the gelatin is functionalized with a plurality of first members of a binding pair; a second layer of gelatin wherein the gelatin is functionalized with a plurality of the first members of the binding pair and the second layer is bound to the first layer via a plurality of second members of the binding pair that are associated with the first members of the binding pair on both the first and the second layers; and a plurality of nanostructures bound to the second members of the binding pair and to one or more particle-binding moieties that selectively bind to the target particles.
    Type: Grant
    Filed: February 3, 2014
    Date of Patent: February 4, 2020
    Assignee: The General Hospital Corporation
    Inventors: Eduardo Reategui, Shannon Stott, Mehmet Toner
  • Patent number: 10550196
    Abstract: Humanized antibodies, capable of specific binding to human CEACAM1 molecules containing human-to-murine back-mutations in non-CDR variable regions, and their encoding polynucleotide sequences are provided. Pharmaceutical compositions comprising these antibodies as well as methods of their use in treating and diagnosing cancer and other conditions are also provided.
    Type: Grant
    Filed: April 27, 2015
    Date of Patent: February 4, 2020
    Assignee: Famewave Ltd.
    Inventors: Tehila Ben-Moshe, Yair Sapir, Ilana Mandel, Gal Markel, Jacob Schachter, Rona Ortenberg, Francis Joseph Carr, Robert George E. Holgate, Timothy David Jones
  • Patent number: 10544224
    Abstract: This disclosure provides a method for treating HPV-positive squamous cell carcinoma of the head and neck comprising administering to the subject an immune checkpoint inhibitor, e.g., an anti-PD-1 antibody or an anti-PD-L1 antibody. The disclosure also provides a method for treating HPV-negative squamous cell carcinoma of the head and neck administering to the subject an immune checkpoint inhibitor, e.g., an anti-PD-1 antibody or an anti-PD-L1 antibody. The subject can be additionally administered another anti-cancer agent.
    Type: Grant
    Filed: July 14, 2016
    Date of Patent: January 28, 2020
    Assignee: Bristol-Myers Squibb Company
    Inventors: Demetrios Manekas, Joseph Grosso, Jeffrey Anderson
  • Patent number: 10533050
    Abstract: The present disclosure provides methods of treating liver cancer and preventing liver cancer recurrence with anti-progastrin antibodies, methods of monitoring treatment efficacy of anti-progastrin therapy for liver cancer, and compositions useful therefore.
    Type: Grant
    Filed: July 22, 2011
    Date of Patent: January 14, 2020
    Assignees: Institut National de la Sante et de la Recherche Medicale (INSERM), Centre National de la Recherche Scientifique (CNRS), Les Laboratories Servier
    Inventors: Leïla Houhou, Anne-Sophie Dumé, Dominique Joubert, Frédéric Hollande
  • Patent number: 10533208
    Abstract: Methods are provided for the prognosis, diagnosis and treatment of various pathological states, including cancer, chemotherapy resistance and dementia associated with Alzheimer's disease. The methods provided herein are based on the discovery that various proteins with a high level of sialylation are shown herein to be associated with disease states, such as, cancer, chemotherapy resistance and dementia associated with Alzheimer's disease. Such methods provide a lysosomal exocytosis activity profile comprising one or more values representing lysosomal exocytosis activity. Also provided herein, is the discovery that low lysosomal sialidase activity is associated with various pathological states. Thus, the methods also provide a lysosomal sialidase activity profile, comprising one or more values representing lysosomal sialidase activity. A lysosomal sialidase activity profile is one example of a lysosomal exocytosis activity profile.
    Type: Grant
    Filed: November 9, 2017
    Date of Patent: January 14, 2020
    Assignee: ST. JUDE CHILDREN'S RESEARCH HOSPITAL
    Inventors: Ida Annunziata, Alessandra D'Azzo
  • Patent number: 10534007
    Abstract: The present invention provides a method for the assay of synucleins in a body fluid or tissue sample, wherein said method comprises the steps of contacting said sample with membrane lipids under conditions enabling binding of the synuclein to said lipids, and the detection of the lipid-bound synuclein by a synuclein-binding agent.
    Type: Grant
    Filed: October 7, 2014
    Date of Patent: January 14, 2020
    Assignee: YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD
    Inventor: Ronit Sharon
  • Patent number: 10519251
    Abstract: The present invention provides multivalent and multispecific binding proteins that are capable of binding two or more antigens, or two or more epitopes. The present invention also provides methods of making and using such multivalent and multispecific binding proteins, including methods of using such binding proteins for prevention or treatment of various diseases, or for detecting specific antigens in vitro or in vivo.
    Type: Grant
    Filed: December 24, 2014
    Date of Patent: December 31, 2019
    Assignee: EpimAb Biotherapeutics, Inc.
    Inventor: Chengbin Wu
  • Patent number: 10500231
    Abstract: The present invention relates to the fields of medicine, cell biology, molecular biology and genetics. In particular, the present invention provides methods to isolate and purify microvesicles from cell culture supernatants and biological fluids. The present invention also provides pharmaceutical compositions of microvesicles to promote or enhance wound healing, stimulate tissue regeneration, remodel scarred tissue, modulate immune reactions, alter neoplastic cell growth and/or mobility, or alter normal cell growth and/or mobility. The present invention also provides compositions of microvesicles to be used as diagnostic reagents, and methods to prepare the compositions of microvesicles.
    Type: Grant
    Filed: March 12, 2014
    Date of Patent: December 10, 2019
    Assignee: University of Miami
    Inventors: Evangelos V. Badiavas, Arsalan Q. Shabbir, Stephen C. Davis
  • Patent number: 10502734
    Abstract: The present invention relates to a system for biodetection applications comprising two basic elements, a substrate with a functionalized surface and a nanoparticle, the system being capable of enhancing the plasmonic effect of the nanoparticle. The invention also relates to a biosensor incorporating such system, in addition to the method for detecting and quantifying a target analyte selected in a sample using such system. Finally, the invention relates to a device which can detect the enhanced optoplasmonic effect of the nanoparticles by means of the system of the invention or by combining the detection of such optoplasmonic effect with the analysis of the changes in the mechanical characteristics in the substrate.
    Type: Grant
    Filed: June 2, 2015
    Date of Patent: December 10, 2019
    Assignee: CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS
    Inventors: Francisco Javier Tamayo de Miguel, Priscila Monteiro Kosaka, Valerio Pini, Montserrat Calleja Goméz, Jose Jaime Ruz Martinez, Daniel Ramos Vega, Maria Ujue Gonzalez Sagardoy
  • Patent number: 10502741
    Abstract: The present invention provides means and methods for selectively detecting activated MALT1 in a sample. Moreover, the present invention provides a method for diagnosing diseases, which are characterized by an increased MALT1 activity. Finally, the present invention provides methods for identifying patients which are amenable to treatment with a therapeutic agent capable of inhibiting MALT1 activity.
    Type: Grant
    Filed: January 20, 2015
    Date of Patent: December 10, 2019
    Assignees: Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umweld (GmbH), Technische Universität München
    Inventors: Daniel Krappmann, Andrea Eitelhuber, Steven Verhelst
  • Patent number: 10502740
    Abstract: An enzyme detection device (1) for detecting the presence, in a sample, of an enzyme capable of modifying a provided substrate (10). The device (1) comprises a substrate which has a modification region (14) that is sensitive to modification by the enzyme from an unmodified state to a modified state. The device (1) further comprises a substrate recognition molecule (16) which binds the modification region (14) in either the modified or the unmodified state. The modification region 14 of the substrate is preferentially bound by the substrate recognition molecule (16) as compared with the enzyme when mixed. The device further comprises a detectable label (18) coupled to the substrate recognition molecule (17).
    Type: Grant
    Filed: January 4, 2016
    Date of Patent: December 10, 2019
    Assignee: Mologic Limited
    Inventor: Paul James Davis
  • Patent number: 10494601
    Abstract: The present invention relates to a method for inducing osteogenic differentiation of mesenchymal stem cells and, more particularly, to a short-time osteogenic differentiation method of culturing cells using a porous membrane and a biodegradable synthetic biogel, whereby the cells do not contact a cell culture container. The present invention can significantly shorten the induction period of osteogenic differentiation, compared to the conventional osteogenic differentiation method, and has an effect of the cells being easily separable after differentiation as well.
    Type: Grant
    Filed: September 15, 2015
    Date of Patent: December 3, 2019
    Assignee: CEFO CO., LTD
    Inventors: Hyun Sook Park, Sun Ray Lee, Ji Won Yang, Seol Chu, Hyun Jung Mo